Investigational drug · Phase 2
Ubamatamab
Also called: REGN4018
Not approved by FDA. In 4 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer.
Phase 2Last checked: Nov 19, 2026Latest source record: Nov 6, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
4
4 still active
All registered trials
7
Any phase or sponsor naming "Ubamatamab"
First trial start
2018
May 21, 2018
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Ubamatamab", any sponsor or status.
Conditions studied
As listed on its trial records.
- Ovarian Cancer
- Fallopian Tube Cancer
- Primary Peritoneal Cancer
- Endometrial Cancer
- Non Small Cell Lung Cancer
- Advanced Non Small Cell Lung Cancer
- Metastatic Non Small Cell Lung Cancer
- Carcinoma Non Small Cell Lung
- Recurrent Ovarian Cancer
- Recurrent Fallopian Tube Cancer
Approved drugs for the same conditions: Small cell lung cancer · Ovarian cancer · Endometrial cancer · Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "Ubamatamab" as an intervention, largest first.
Regeneron PharmaceuticalsRegeneron (REGN)
NCT03564340 · 890 participants (planned) · Start May 21, 2018 · Primary completion May 10, 2027
Drug: Ubamatamab; Cemiplimab and 2 more · For: Recurrent Ovarian Cancer; Recurrent Fallopian Tube Cancer; Recurrent Primary Peritoneal Cancer and 3 more
Sites: Birmingham, Alabama; Boston, Massachusetts; Rochester, Minnesota · 54 sites in all
Regeneron PharmaceuticalsRegeneron (REGN)
NCT04590326 · 612 participants (planned) · Start Dec 8, 2020 · Primary completion Nov 8, 2028
Drug: REGN5668; Cemiplimab and 3 more · For: Ovarian Cancer; Fallopian Tube Cancer; Primary Peritoneal Cancer and 1 more
Sites: Duarte, California; Irvine, California; Orange, California · 28 sites in all
- Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian CancerPivotal-lookingRecruiting
Regeneron PharmaceuticalsRegeneron (REGN)
NCT06787612 · 397 participants (planned) · Start May 28, 2025 · Primary completion Jun 30, 2028
Drug: Ubamatamab; Bevacizumab and 5 more · For: Ovarian Cancer; Fallopian Tube Cancer; Primary Peritoneal Cancer
Sites: Birmingham, Alabama; La Jolla, California; Los Angeles, California · 56 sites in all
- A Study to Investigate Ubamatamab With and Without Marlotamig (REGN7075) in Adult Participants With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)Pivotal-lookingRecruiting
Regeneron PharmaceuticalsRegeneron (REGN)
NCT07154290 · 300 participants (planned) · Start Mar 18, 2026 · Primary completion Jun 10, 2030
Drug: Ubamatamab; Marlotamig and 1 more · For: Non Small Cell Lung Cancer; Advanced Non Small Cell Lung Cancer; Metastatic Non Small Cell Lung Cancer and 1 more
Sites: Birmingham, Alabama; Goodyear, Arizona; Irvine, California · 18 sites in all
ARCAGY/ GINECO GROUPAcademic, hospital or other
NCT07637851 · 43 participants (planned) · Start Aug 2026 · Primary completion Sep 2028
Drug: Ubamatamab; Chemotherapy and 2 more · For: Ovarian Cancer
Sites: Bordeaux, France; Caen, France; Dijon, France · 11 sites in all
M.D. Anderson Cancer CenterAcademic, hospital or other
NCT06444880 · 40 participants (planned) · Start Oct 9, 2024 · Primary completion Jul 31, 2027
Drug: Ubamatamab; Cemiplimab · For: SMARCB1-Deficient Malignancies; Epithelioid Sarcoma; Renal Medullary Carcinoma
Sites: Houston, Texas
- Compassionate Use of UbamatamabAvailable
Regeneron PharmaceuticalsRegeneron (REGN)
NCT07502716
Drug: ubamatamab · For: Renal Medullary Carcinoma (RMC); Epithelioid Sarcoma
Newest research
PubMed records naming it or its code names, newest first.
- Mucin 16-Directed Therapy in Pediatric Sarcomas: Case Evidence of Ubamatamab Efficacy in Epithelioid Sarcoma and Its Implications for Other Sarcoma Subtypes.
Connolly DM, Revon-Rivière G, Chami R, et al. · JCO Precis Oncol 2025
- Translational findings support regimen selection for first-in-human study of ubamatamab (MUC16ߙ×ߙCD3 bispecific antibody) in patients with recurrent ovarian cancer.
Zhu M, Madia P, Crawford A, et al. · Clin Transl Sci 2024
- A Mucin 16 bispecific T cell-engaging antibody for the treatment of ovarian cancer.
Crawford A, Haber L, Kelly MP, et al. · Sci Transl Med 2019
Also in development for Ovarian Cancer
- SHR-A1811Trastuzumab RezetecanPhase 327 trials
Jiangsu HengRui Medicine Co., Ltd. · Advanced Colorectal Cancer, Recurrent or Metastatic Cervical Cancer, Ovarian Cancer
- RilvegostomigAZD2936Phase 325 trials
AstraZeneca · Biliary Tract Cancer, Gastric Cancer, Non-small Cell Lung Cancer
- GiredestrantRO7197597, GDC-9545Phase 316 trials
Roche (Genentech) · Early Breast Cancer, Breast Cancer, Estrogen Receptor (ER)-Positive, HER2-negative, Locally Advanced or Metastatic Breast Cancer
- SG001enlonstobart, Enlonstobart will be administrated on a 14-day cyclePhase 315 trials
CSPC Megalith Biopharmaceutical Co.,Ltd. · HER2-positive Gastric Cancer, Esophageal Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma
- FianlimabREGN3767Phase 311 trials
Regeneron · Melanoma, Non-small Cell Lung Cancer, Hepatocellular Carcinoma
- LBL-024Phase 311 trials
Nanjing Leads Biolabs Co.,Ltd · Advanced Solid Tumour, Advanced Extrapulmonary Neuroendocrine Carcinoma, Metastatic Colorectal Carcinoma
- R-DXdDS 6000a, MK-5909Phase 310 trials
Merck & Co. · Fallopian Tube Cancer, Ovarian Cancer, Peritoneal Cancer
- SaruparibAZD5305Phase 310 trials
AstraZeneca · Prostate Cancer, Ovarian Cancer, Endometrial Cancer
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Regeneron.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.